Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental CAR T-Cell therapy targets rare testicular cancer

NCT ID NCT05634785

Completed Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This phase 2 study tested a new treatment for nonseminomatous germ cell tumors (a type of testicular cancer) that had not responded to standard therapy. The treatment used the patient's own immune cells (T cells) that were genetically modified to recognize and attack cancer cells carrying the CD30 protein. Only 2 people took part, and the main goal was to see if the tumors shrank. The study also collected blood and tumor samples to learn more about how the modified cells work in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CD30-targeted CAR T-cells (ATLCAR.CD30 cells) plus cyclophosphamide
What this could lead to
If it works, this could point toward a new treatment option for hard-to-treat germ cell tumors.
What could go wrong
This was a very small, early-phase trial with only 2 participants, so results are not conclusive. The treatment may not shrink tumors or could cause side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

germ cell tumor Neoplasms, Germ Cell and Embryonal nongerminomatous germ cell tumor Nonseminomatous germ cell tumor testicular non-seminomatous germ cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERM CELL TUMOR NONSEMINOMATOUS GERM CELL TUMOR

Contacts and locations

Locations

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.